Latest Conference Articles

Collaboration between health system specialty pharmacists and pharmaceutical manufacturers can benefit patients in the long run.

Collaboration between health system specialty pharmacies and manufacturers can benefit patients in the long run.

Addressing requirements around FDA interchangeability designations can increase the adoption of biosimilar substitutions at the pharmacy level.

A recent bill introduced to Congress is intended to prevent product hopping, a practice that extends exclusivity and hinders the adoption of biosimilar therapies.

Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.

One notable incentive includes the launch of biosimilars at both low- and high wholesale acquisition costs.

Pharmacists can help financial decision makers understand the value of biosimilar therapies.

Savings associated with biosimilar uptake are projected to reach $181 billion through 2027.

The role of health care specialty pharmacies has expanded.

Paying for these new therapies, that may be curative for patients, remains a challenge.

“I think in those situations where you can use the lower cost of the drug, you should, because it's going to help the overall societal perspective. That begins to break down, though, when that low-cost drug is the one that you're losing money on,” said Scott Soefje in a Q&A on balancing cost and margin at a site of care.

From medication adherence to patient counseling, clinical pharmacists at health system specialty pharmacies can play a role in reducing health care costs.

A Q&A with Karen Fancher, PharmD, associate professor of pharmacy practice at Duquesne University School of Pharmacy, on applying ethical principles to manage complex situations in oncology pharmacy.

A Q&A with Kirollos Hanna, PharmD, director of pharmacy at Minnesota Oncology, on the current and future landscape of bispecific antibodies in myeloma treatment.

A Q&A with Douglas Hoey, CEO of NCPA, on ways to change the pharmacy payment model and deceptive practices being employed by PBMs.

At AAP 2024, Kathy Campbell, PharmD, discussed obstacles that pharmacies may face when transitioning to a wellness-focused approach.

According to Scott Soefje, PharmD, understanding nuances across sites of care can help health care providers optimize patient care delivery while ensuring financial viability across all settings.

Karen Fancher, PharmD, addresses how hearing the perspectives of colleagues can offer invaluable support to shape individualized approaches to ethical dilemmas in oncology pharmacy.

While prioritizing either cost or margin may be necessary at a site of care, big picture items, such as societal responsibility and long-term health care affordability, should guide financial analyses, said Scott Soefje, PharmD.

A Q&A with Joe McKamey, general manager at Marcrom’s Pharmacy in Manchester, Tennessee.

Kathy Campbell, PharmD, discusses why she believes wellness and proactive health are the future of pharmacy and the unique value they offer compared to traditional models.

According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.

As the potential grows to use emerging bispecifics in earlier lines of myeloma therapy, so does the potential to induce better patient outcomes, said Kirollos Hanna, PharmD.

A Q&A with Douglas Hoey, CEO of NCPA, on how the new provision from CMS requiring DIR fees at the point of sale is impacting independent pharmacies in 2024.

At AAP 2024, the Cardinal Health Pharmacy Transitions Services team hosted a session outlining how best to go about selling and buying a pharmacy.

Joe McKamey, general manager at Marcrom’s Pharmacy, highlights the potential pitfalls or misconceptions that pharmacies may encounter when opening a Medicare-focused insurance agency.

“Every pharmacist raises their hand and takes an oath before they graduate to put patients first,” said Bruce Berger, PhD, FAPhA. “But what happens when you exist in an environment every single day where that’s impossible?”

Eric Fromhart, co-founder and chief growth officer at Aventi Health, discusses how pharmacies can use 340B to increase profits and how they can avoid any potential risks when participating in the program.